RT Journal Article
T1 Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial
A1 Murcia Casas, Belén
A1 Carrillo Linares, Juan Luis
A1 Baquero Aranda, Isabel
A1 Rioja Villodres, José
A1 Merino Bohórquez, Vicente
A1 González-Jiménez, Andrés
A1 Rico Corral, Miguel Ángel
A1 Bosch, Ricardo
A1 Sánchez Chaparro, Miguel ángel
A1 García-Fernández, María Dolores
A1 Valdivielso-Felices, Pedro
K1 Medicina
K1 Ensayos clínicos
K1 Medicamentos - Ensayos
AB Pseudoxanthoma elasticum (PXE) is characterized by low levels of inorganic pyrophosphate (PPi) and a high activity of tissue-nonspecific alkaline phosphatase (TNAP). Lansoprazole is a partial inhibitor of TNAP. The aim was to investigate whether lansoprazole increases plasma PPi levels in subjects with PXE. We conducted a 2 × 2 randomized, double-blind, placebo-controlled crossover trial in patients with PXE. Patients were allocated 30 mg/day of lansoprazole or a placebo in two sequences of 8 weeks. The primary outcome was the differences in plasma PPi levels between the placebo and lansoprazole phases. 29 patients were included in the study. There were eight drop-outs due to the pandemic lockdown after the first visit and one due to gastric intolerance, so twenty patients completed the trial. A generalized linear mixed model was used to evaluate the effect of lansoprazole. Overall, lansoprazole increased plasma PPi levels from 0.34 ± 0.10 µM to 0.41 ± 0.16 µM (p = 0.0302), with no statistically significant changes in TNAP activity. There were no important adverse events. 30 mg/day of lansoprazole was able to significantly increase plasma PPi in patients with PXE; despite this, the study should be replicated with a large number of participants in a multicenter trial, with a clinical end point as the primary outcome.
PB MDPI
YR 2023
FD 2023-03-03
LK https://hdl.handle.net/10630/26571
UL https://hdl.handle.net/10630/26571
LA spa
NO Murcia Casas B, Carrillo Linares JL, Baquero Aranda I, Rioja Villodres J, Merino Bohórquez V, González Jiménez A, Rico Corral MÁ, Bosch R, Sánchez Chaparro MÁ, García Fernández M, Valdivielso P. Lansoprazole Increases Inorganic Pyrophosphate in Patients with Pseudoxanthoma Elasticum: A Double-Blind, Randomized, Placebo-Controlled Crossover Trial. International Journal of Molecular Sciences. 2023; 24(5):4899. https://doi.org/10.3390/ijms24054899
NO Funding for open access charge: Universidad de Málaga
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026